Patents by Inventor Vincent P. Rocco

Vincent P. Rocco has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5-HT1A and 5-HT1D&agr;dalpha antagonists
    Patent number: 6376505
    Abstract: A class of novel substituted-aryloxy-2-ol-3-(4-spiro-(alkanedioxy)isobenzofuranyl- and phthaloyl-piperidine) derivatives is disclosed useful as 5-HT1A and 5-HT1D&agr; antagonists.
    Type: Grant
    Filed: November 22, 1999
    Date of Patent: April 23, 2002
    Assignee: Eli Lilly and Company
    Inventor: Vincent P. Rocco
  • Compounds having effects on serotonin-related systems
    Patent number: 6172073
    Abstract: A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.
    Type: Grant
    Filed: March 27, 1998
    Date of Patent: January 9, 2001
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, David J. Hibschman, Joseph H. Krushinski, Jr., Thomas E. Mabry, Jeffrey S. Nissen, Kurt Rasmussen, Vincent P. Rocco, John M. Schaus, Dennis C. Thompson, David T. Wong
  • 5.alpha.-reductase inhibitors
    Patent number: 6150375
    Abstract: A series of benzoquinolin-3-ones are pharmaceuticals effective in treating conditions consequent on both Type I and Type II 5.alpha.-reductase.
    Type: Grant
    Filed: December 11, 1998
    Date of Patent: November 21, 2000
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Loretta A. McQuaid, Blake L. Neubauer, Vincent P. Rocco, Kevin L. Haehl, Thomas J. Kress, James P. Wepsiec
  • Inhibition of serotonin reuptake
    Patent number: 6046215
    Abstract: This invention provides compounds and a method for the inhibition of serotonin reuptake in mammals.
    Type: Grant
    Filed: July 30, 1998
    Date of Patent: April 4, 2000
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Daniel J. Koch, Thomas E. Mabry, Jeffrey S. Nissen, Vincent P. Rocco, Yao-Chang Xu
  • Inhibition of serotonin reuptake
    Patent number: 5846982
    Abstract: This invention provides compounds and a method for the inhibition of serotonin reuptake in mammals.
    Type: Grant
    Filed: May 22, 1997
    Date of Patent: December 8, 1998
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Daniel J. Koch, Thomas E. Mabry, Jeffrey S. Nissen, Vincent P. Rocco, Yao-Chang Xu
  • Compounds having effects on serotonin-related systems
    Patent number: 5789402
    Abstract: A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: August 4, 1998
    Assignee: Eli Lilly Company
    Inventors: James E. Audia, David J. Hibschman, Joseph H. Krushinski, Jr., Thomas E. Mabry, Jeffrey S. Nissen, Kurt Rasmussen, Vincent P. Rocco, John M. Schaus, Dennis C. Thompson, David T. Wong
  • Compounds having effects on serotonin-related systems
    Patent number: 5741789
    Abstract: A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: April 21, 1998
    Assignee: Eli Lilly and Company
    Inventors: David J. Hibschman, Joseph H. Krushinski, Jr., Kurt Rasmussen, Vincent P. Rocco, John M. Schaus, Dennis C. Thompson
  • Compounds having effects on serotonin-related systems
    Patent number: 5627196
    Abstract: A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 6, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, David J. Hibschman, Joseph H. Krushinski, Jr., Thomas E. Mabry, Jeffrey S. Nissen, Kurt Rasmussen, Vincent P. Rocco, John M. Schaus, Dennis C. Thompson, David T. Wong
  • 5.alpha.-reductase inhibitors
    Patent number: 5622962
    Abstract: A series of benzoquinolin-3-ones are pharmaceuticals effective in treating conditions consequent on both Type I and Type II 5.alpha.-reductase.
    Type: Grant
    Filed: May 11, 1995
    Date of Patent: April 22, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Loretta A. McQuaid, Blake L. Neubauer, Vincent P. Rocco
  • 5.alpha.-reductase inhibitors
    Patent number: 5622961
    Abstract: A series of benzoquinolin-3-ones are pharmaceuticals effective in treating conditions consequent on both Type I and Type II 5.alpha.-reductase.
    Type: Grant
    Filed: May 11, 1995
    Date of Patent: April 22, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Loretta A. McQuaid, Blake L. Neubauer, Vincent P. Rocco
  • Compounds having effects on serotonin-related systems
    Patent number: 5614523
    Abstract: A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 25, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Joseph H. Krushinski, Jr., Kurt Rasmussen, Vincent P. Rocco, John M. Schaus, Dennis C. Thompson, David T. Wong
  • Compounds having effects on serotonin-related systems
    Patent number: 5576321
    Abstract: A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 19, 1996
    Assignee: Eli Lilly and Company
    Inventors: Joseph H. Krushinski, Jr., Kurt Rasmussen, Vincent P. Rocco, John M. Schaus, Dennis C. Thompson